Akeso Shares Exciting Preclinical Data on IL-1RAP Antibody AK135 at SITC 2025 Akeso reveals promising preclinical findings regarding its antibody AK135 targeting IL-1RAP at SITC 2025, showcasing improved pain relief and safety profiles.

Akeso Shares Exciting Preclinical Data on IL-1RAP Antibody AK135 at SITC 2025 #Hong_Kong #Akeso #National_Harbor,_Maryland #SITC #AK135